the of oncology. a we've essentially have that more in new repositioned relatively say our you, And XX Thank and morning, good we predictive pleased made short I'm It very to vision been Glenn, and restructured, I for period with that strategic than now time. progress everyone. months since has slightly implemented
trade bolstered identified only and most of our our further and one have the We have intellectual previously valuable unutilized property assets, secrets. but significant within we company, assets not
and on what we unique to us. important a have but is progress XXXX capabilities, drug compelling offering of and was It set has to of commercial first a assets development accelerating that us articulate invisible. the we It incorporate now a Sometimes set to for transitional easy. year believe for was oncologic business lessons integrated global for market and was is begun forward. necessary. our also responding Drying year is and scale. year accelerating and on this It stage enabled from learning difficult discovery to valuable knowledge. the Rebuilding development in further refine growth moving never initiatives our a
who evolving story, those be unique Predictive in As in our market. drug is a for and new to reminder, Oncology may the particularly artificial intelligence discovery
are together We cutting-edge knowledge wet our drug a and specific proprietary XXX,XXX and to active digitized biobank incorporated tumor XXX,XXX company longitudinal years PEDAL patient than more technology samples, bring CLIA to a more is XX into that learning able of currently with intelligence certified being more slides, artificial the pathology than than platform. lab of and data, response which our only are
vitro an of than to methodology expanding those is experimentation. with efficient, silico We more of property. and predictions highly validated generates paraffin-embedded predictions human which and portfolio proprietary artificial of formalin-fixed, to XX,XXX an can more accurate platform, assets, blocks add how intellectual in tissue supports CLIA reservoir tumors platform, scientific a intelligence This respond of but than that just drugs in
development heterogeneity drugs have of to development, XX% that drug phases we patients we accuracy. a respond validated tumor are drug to have our given will partners demonstrated the into clinical Our our pedal to success potential technically, or well lesser scientifically into which the before prioritization of clearly a us and earliest predict to commercially human and degrees clinical future that Having biobank able critical enables insight tumor with greater allows of gain introduce initiated. are platform, if trials and
The probability documented the that been success failure and the risky, and implication mitigate area particularly expedite development is before. can of risk they in It that of ways drug expensive is has developers have in well that never inherently of the drug for been seen oncology.
past XX of all drugs drugs Over were I In less trials X% years, approved fact, there the for the approved approximately ultimately actually in trials. clinical been other Only words, Phase are have enter that than for cancer selected by use. FDA. XXX X,XXX which of clinical
our are might of the predict succeed dollars thousands we may to fail the able power many predicted the stages candidates advancing to of are harnessing of have in in risk that of developers of clinic drug save and later millions drug clinical the most hours, development pedal likely of avoiding candidates trials. By man we platform, pursuing while which
With tumor also partners able proprietary models. are PEDAL, that development training to AI drug response aid generate we novel drug can data in our
speaks archive own, historical While comprehensive others tumor cannot response to developed they and expertise in currently domain our drug what the industry certainly already duplicate we data and successfully have replicate samples, that into of heterogeneity unique from simply have ability attempted This early drug the into a introduce integrate sources we tumor possess. data to solution our single discovery. the importance of volumes multiple about that can
years, gives take an that reproduce. Moreover, advantage our not and we of would to biobank data enduring drug large repository believe if decades, us response competitive
a with like identify to the with destiny entire to provide be likely we fundamental cancer we don't but determine to the populations use and discuss own sets largest world's ourselves, position private more XXXX, most that have to horizons. license not would and inhibitor evaluate with of been of inevitably, Ultimately, our controlling of those candidates glutaminase could, research reference treatment patient an the preclinical Recall our compounds. these we which biological in respect those funder types owning X now of engagements significance candidates are to the to cancer of drug as experimentation, assets. cancer working are big to drug on only not respond continuum if of to will and control compounds wet in we of lab means we research with computational their as directly beginning data, response Although pathology update drug some pharma.
I CRH, capacity, samples, from to notable this much that historical
In and we lab to deliver of subpopulations only compounds X responsive Armed pursuing most were significant ovary. able of strongest a actual this likely candidates to weeks identify able of lung different time, and time are and this that now that results process, the to development more campaign, position a were tumor prioritize matter those in is the targets colon, across was clinic. tumor in succeed a of CRH the ideal liver, the to to information, their few first with in save types by only the resources which of types: patients on
perform here provide types of including defining to next to the tumor whole of the interest sampling much and/or the of in DNA extensive whole step samples. might or molecular The or use the X presumably more sequencing, for information tumor subpopulations patient or responsive transcriptome. of This be interest, would X more responders better purpose RNA exome of
other and reference crucial CRH point engagement our as engage leading discovery our companies. with third-party cancer technology development PEDAL From of this drug as important drug and serves validation provides an with we perspective,
overall cancer. cancer we Magee-Womens could ovarian short machine with multi-omic represents UPMC last learning malignancies. to and build the deadliest predict long-term we Hospital, that now all and a treatment completed models of epithelial successfully need survival unmet Ovarian quarter multiyear that in study in ovarian an announced oncology Turning cancer gynecologic retrospective being
is cases, of frontline are sensitive at to these in the incurable. relapse disease experience XX% percentage, chemotherapy While which these equal approximately will ultimately cancers women an
of ovarian primary is cancer standard-of-care from key Outside The identify universal patients that to no there and determine treatment study agents. included Magee overall sequence of and the was XXX features endpoints. drive the decision path survival chemotherapy, to agents' data timing designed chemotherapeutic
deliver to accuracies, cancer levels were We population. the say and learning we ability ovarian prognostic our are an identify to very predictive subgroups with strong that within high demonstrated patient pleased of capabilities models machine to able
engage development affect with AI-driven model positively of the tool, importance One on therapies would we We overall Magee support of and for an practice. application models decision these individual to features tailor survival. additional be prognostic continue having as methods potential for the into to patients identified clinical that incorporating leveraging the
such Another more and clinical designs. efficient trial effective drive be to would application
ongoing, possibility certainly models are The in clinical parallel exist pathology combinations. reevaluate discussions rescue, applications does models drug types and for we drug these well are this While utilizing as data utility. as than other to information predictive drug and this for purposes leads, cancer to digital for other repurposing new biomarker develop
Magee data and enrich aggregation more modeling, of in a possession. our to Leaning through them insights digitization is significant recently we than development featurization including key curation forward. who Delivering efforts to our can and and such highly slides heavily data Foundation R.K. models CROs pathology on in fact, activities, the access moving value and regarded a especially the as proposal Mellon our clinical information, outcome unique and to evidence, XXX,XXX and further in and to developers from necessary for corporate sets currently this business factor drug benefit gaining sequencing of the collaborators submitted
aggregate, players confirm Again, analyze patient in Magee as clinical the drug apart industry, models heterogeneity that to targets both to it patient is to multi-only in our responses heterogeneous the reason patient of into oncology a our us AI successfully without predict development. CRH is both incorporated patient new why with is populations. that drugs ability and work Our others established stages later truly fail across model major question, and certain heterogeneity and sets data from
past. have Turning discussed we in other that the now to collaborations
give Center as Cvergenx, on Let recent the a the of the Advancement for me Space. and submission in you as most Fuji Science brief update well FluGen to
announced therapy we artificial first genomics-based may intelligence. recall drug a last precision approach and Cvergenx that with the to ever radiation You develop collaboration discovery February, to using
identify was the to of radio maximize expertise and in biomarker leverage power novel and proficiency collaboration intelligence Cvergenx' objective Oncology's in to The and protector this Predictive sensitizer development artificial of drugs. radio combined
progress, more we in using developed well-established Over to predict exposures having models have than different for X,XXX changes trained expression significant past year, the drug evaluated, or databases. now team made radiosensitivity
well the or models, workers radiation. of basis or from radio clinical of the these screen a to form repurposing, patients an protect vast the military I human nuclear sensitize and radiotherapy. of energy example, drug findings protectors libraries to subjects planning industry however.
Using and combinations extend and sensitizers of SBIR in of these potential compounds for screen identifying proactively NIH the drugs beyond repurpose effects Phase grant the setting, we significance The treatment of the optimize radio development drugs, can in and These drug receiving accelerate in
in potentially have those respect several important in the to And Cvergenx applications. of So has we data utility our leveraged work expand may broad sets, process, which important able a with number commercialization. ways with be to across been
First, identify, therapeutic tumor of interactions and individuals repurpose radiation resistance to resistant drugs. optimize or for or clinical samples the to between compounds; combine screen protective third, sensitive and to sensitivity for screen sensitizing second, patient efficiency develop radio radio or novel or radiotherapy; or
more but and These new activities are interesting created not developments, opportunities. synergistic isolated that
you technology For Science his Station. astronaut relationship DeLucas, recently to on might led in NASA, with example, Because we by a Advancement Space Larry the senior experience for Station. Dr. Biologics as and The Group the Space of submitted given remember, of Center former the for that our scientist use proposal, Space our is and
and now of in membrane The size, GPCRs cell of and improve space other biologically this that expression classes. known is have environment differentiation the gravity enhances can increase system team his rate and expressed which GPCRs. yield G-protein-coupled for receptors, also growth and micro significant to the cell quantities reason a of protein membrane the novel active produce as protein Larry developed
and opportunity, and practical Company, this has more with Merck also to led Space. is The immediate however, & concept Redwire collaborations that OCMS
novel broadly we for of property we receptors. just system applications. expression G-protein-coupled to of biopharma in development position a for and to numerous a will As a intellectual purification drug out-license result have this filed be these When in issued, for developments, method technology
grant as project approval grant been which this the in first-of-its-kind flu the our entered dollar a call funded has awarded, to the from IIb that details the to to develop Oncology coming Predictive Defense. of weeks, of market Phase a the a by submitted be last pleased pending remember of now multimillion disclosed a part NIH. Defense vaccine has may by Department will novel been I'm of collaboration FluGen and Department that to for You which say into
the Oncology Predictive and lastly, FluGen's Oncology to detection Predictive the injectable for sustainable crucial critical more a technologies also role vaccine pharmaceuticals their novel our and state, which a solution play few intention as And process. a products. stable in treatment and will will in drug development in and next Fuji is refrigerated requirement making biological announce a in weeks endotoxin co-market
According market Insights, Market to to by $XX drug projected of a expected grow Future X.X%, billion injectable recent is report reaching $X the by value a billion by XXXX.
the recap to Josh would Before to recent call over review turning like to activity. financials, I the conference
XXXX, company care well During towards at health among of the investor months our conferences presence we meaningful collaborators. had as initial geared of investors raising as awareness institutional several potential high-quality a
Conference. Biotech and include Orleans Artificial Intelligence Annual precision the These and Cancer in the during panel sat in Drug on New Based New Wainwright medicine Conference Showcase the XXXX I topic of Oncology BIO Investor Discovery Development which discussing San First York, Francisco, a CEO H.C. the Conference New finally, and in
we for critical both our long-term shareholders. Blacher. I events turn At Josh conference appearances partners our the point, more this effort view and and of call have for We element these to our XXXX, the create balance Josh? a of to as over value such will planned
